Brief: Lipigon Pharmaceuticals Q4 Oper Loss Narrows To SEK 7.8 Mln
22/02/2024 07:20
Feb 22 (Reuters) - Lipigon Pharmaceuticals AB LPGO.ST :
* Q4 OPERATING LOSS SEK 7.8 MILLION VERSUS LOSS SEK 9.2
MILLION
YEAR AGO
Source text for Eikon: ID:nBQN8znzg9
Further company coverage: LPGO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lipigon Pharmaceuticals AB
See all newsBrief: Nasdaq To Delist Lipigon Pharmaceuticals From First North Growth Market
Brief: Lipigon Expected To Be Removed From Trading On Nasdaq Stockholm On May 18
Brief: Lipigon Proposes To Delist Company From Nasdaq First NGM
Brief: Lipigon Pharmaceuticals Oct-Dec Oper Loss At SEK 7.2 Mln
Brief: Lipigon Pharmaceuticals Aims To Reduce Cost Base By Two-Thirds